Abstract Committee Review

← Go back

Abstract TitleReview of Phase 1 Pharmacodynamic Models to Characterize Botulinum Neurotoxins: Ability to Assess Onset, Duration, Diffusion, and Pain Threshold in Early Clinical Development
First AuthorMiss Irene Sunwoo
StatusApproved
Comments to Author

To improve the clarity of the abstract, it would be beneficial to include an explanation of how the measurements are performed:

  • In the EDB model, PD effect is measured by the compound muscle action potential - Please explain how this is measured for non-neurophysiologists
  • The anhidrosis model evaluates the inhibition of sweat production - Can you clarify again how this is measured
  • capsaicin-induced pain model... determine the pain threshold - How is this measured?
  • GL is an aesthetic indication... selectively weaken muscles - Please clarify how this is objectively measured?
ReviewerBiering-Sørensen